Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy

Figure 1 Kaplan-Meier estimates of progression-free survival from the date of apheresis in patients with relapsed/refractory multiple myeloma who underwent T-cell collection for planned B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy (n = 99). Line definitions: The blue line denotes patients who proceeded to chimeric antigen receptor T-cell infusion (infused cohort, n = 87). The purple line denotes patients who underwent apheresis but never received an infusion (non-infused cohort, n = 12). Progression-free survival was measured from the date of apheresis (day 0, index date) to the date of first documented progression by International Myeloma Working Group criteria or death from any cause, whichever occurred first; patients alive and progression-free were censored at the date of last documented disease assessment (data cut-off 12 July 2024). Vertical tick marks on each curve indicate censored observations; the shaded bands, where shown, represent 95%CIs; the table beneath the X-axis reports the number of patients at risk in each group at each 3-month interval. Median progression-free survival was 17.5 months in the infused cohort vs 1.5 months in the non-infused cohort. The X-axis shows time in months from apheresis; the Y-axis shows the estimated probability of remaining alive and progression-free. PFS: Progression-free survival.